A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Trifluridine and Tipiracil (LONSURF)

Nucleoside Analog Antiviral class · 2 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval2015-09-22
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
652 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Trifluridine and Tipiracil used for?

Trifluridine and Tipiracil is a Nucleoside Analog Antiviral medication tracked in Medicare Part D.

Is there a generic for Trifluridine and Tipiracil?

Yes. 4 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Trifluridine and Tipiracil?

NADAC pricing data not currently available for this drug.

Is Trifluridine and Tipiracil on the FDA shortage list?

No. Trifluridine and Tipiracil is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nucleoside Analog Antiviral2 alternatives in D1
01
Ribavirin
Brand: Virazole
Lowest NADAC
4Generic mfrs
$413,762CY24 Part D spend
Compare →
02
Trifluridine
Nucleoside Analog Antiviral
$22.20Lowest NADAC
1Generic mfrs
$2.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.